Microdialysis and Pharmacokinetic Study of TR-701

Phase 1 Completed 15 enrolled Merck & Co., Inc.

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701

Timeline

Start: 2008-04-04
Primary completion: 2008-08-12
Completion: 2008-08-12

Publications

Results Sahre M, Sabarinath S, Grant M, Seubert C, Deanda C, Prokocimer P, Derendorf H. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012 Jul;40(1):51-4. doi: 10.1016/j.ijantimicag.2012.03.006. Epub 2012 May 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	0.36 ug	Other
Subject	Tedizolid Phosphate	Small molecule	600 mg	Oral

Indications

No indication recorded.